For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
There is an opportunity cost with healthcare spend, including laboratory tests
+Print Archive
Comment
There is an opportunity cost with healthcare spend, including laboratory tests
Wednesday 22 May 2019, 05:00 AM

Laboratories can and do decline to perform tests that are not indicated, but this is time-consuming
With the current focus on demand management and the ever-present pressure on health costs, will cost-signalling by a transparent listing of test prices during test ordering be about to make a comeback? Regular From the Lab contributor Arlo Upton explains
Key points, The funded model of laboratory testing does not make prices transparent for referrers.
At $138 per New Zealander per year, the laboratory-testing bu, Arlo Upton, Arlo Upton is a clinical microbiologist for Southern Community Laboratories in Dunedin
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.